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Harry A van DiepenAbstract
Background: Nomegestrol acetate (NOMAC), a synthetic progestogen derived from 19-nor-progesterone, recently
completed clinical trials for use with 17beta-estradiol in a new monophasic combined oral contraceptive. In this
review, published as well as previously unpublished preclinical studies that detail the effects of NOMAC on
estrogenic, progestogenic, and androgenic systems, as well as mineralocorticoid, glucocorticoid, bone, and
metabolic indices are described.
Methods: In vitro assays to determine NOMAC structure-activity relationships used tissue derived from rat uteri.
Transactivation profiles were performed using Chinese hamster ovary (CHO) cells transfected with cDNAs encoding
human steroid receptors. Estrogenic and anti-estrogenic activities were monitored in vivo in rats as well as in vitro in
human breast cancer cells. Standard in vivo techniques were used in rats to determine progestational activity;
antigonadotropic, androgenic, mineralocorticoid, and glucocorticoid activities; as well as effects on bone and other
metabolic indices. Ovulation inhibition was monitored in rats and primates. NOMAC’s effects on cardiovascular
systems were determined in dogs and primates.
Results: NOMAC was without significant agonistic or antagonistic activity for estrogen receptor alpha or beta
in vitro, and inhibited ovulation in rats and monkeys (2.5 mg/kg and 1 mg/kg, respectively). NOMAC lacked
androgenic, antimineralocorticoid, glucocorticoid, and metabolic activity and exhibited moderate anti-androgenic
activity in rats. NOMAC did not affect bone mineral density (BMD) in rats or hemodynamic and electrophysiologic
parameters in dogs and primates.
Conclusions: NOMAC is a selective progestogen structurally similar to progesterone that has modest
anti-androgenic activity and does not affect lipid or carbohydrate metabolism, BMD, or many cardiovascular
parameters in selected animal models.
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Most combined oral contraceptives (COCs) in use today
contain a synthetic progestogen (predominantly 19-
nortestosterone derivatives) and a synthetic estrogen,
ethinyl estradiol (EE). In the early 1980s, nomegestrol
acetate (NOMAC), a progestogen derived from 19-
nor-progesterone, was synthesized (Figure 1) [1-3].
Although used clinically for treatment of climactericCorrespondence: havandiepen@gmail.com
Women’s Health Department, Merck Sharp & Dohme (MSD) Corp., Oss, The
Netherlands
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reproduction in any medium, provided the orsymptoms [4], NOMAC was recently combined with
17β-estradiol (E2) to be used in a new COC [5-10].Methods
In this article, we present both previously published and
unpublished data to deliver a complete preclinical
pharmacological profile of NOMAC. The studies were
approved by the review board for animal experimentation
at Merck Sharp & Dohme (MSD, Oss, The Netherlands)
or at Theramex (Monaco) and were performed in accord-
ance with the principles and procedures described in the
European Union guidelines for the care and use oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Structures of progesterone [2] and NOMAC [3].
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of the mean unless otherwise indicated. Comparisons be-
tween groups were analyzed using analysis of variance
(ANOVA) models, unless otherwise indicated and statis-
tical significance was defined as P<0.05.
Results
In vitro progestogenic activity
The in vitro progestogenic activity of NOMAC was ini-
tially assessed by studying its structure-activity relation-
ship with specific ligands on several cytosolic steroid
receptors [11]. The relative binding affinity (RBA) of
NOMAC for the rat uterine progesterone receptor (PR)
is very similar to the binding affinity of progesterone.
After 2 and 24 hours of incubation with rat uterine PR,
the RBA of NOMAC (relative to progesterone) was 72%
and 92%, respectively.
Duc et al. [12] determined the apparent binding con-
stant at equilibrium (kd), maximum concentration of bind-
ing sites (Bmax), the dissociation rate constant k−1, and the
specific RBA (relative to progesterone) of radiolabeled
NOMAC to PR derived from the uteri of estrogen-primed
rats. In their studies, NOMAC had high specificity for rat
uterine PR; saturation occurred at approximately 30 nM.
Nonspecific binding was very low, accounting for only5-7% of total binding. Determination of the specific bind-
ing constants indicated that NOMAC had a kd and Bmax
of 5.44 ± 1.27 nmol/L and 1.51 ± 0.11 pmol/mg protein,
respectively. In addition, it was determined that NOMAC
binds avidly, but is slow to dissociate from rat uterine PR
(k−1= 4.9 ± 0.5 × 10
–5 s–1).Transactivation profile
Receptor-binding experiments, although useful, do not
distinguish between agonistic and antagonistic activity.
van Diepen et al. [13] used established cellular assays
[14-16] to determine the agonistic and antagonistic pro-
files of NOMAC, levonorgestrel (LNG), drospirenone
(DRSP), dienogest (DNG), and progesterone in Chinese
hamster ovary (CHO)-K1 cells that were stably trans-
fected with cDNAs encoding human receptors, including
progesterone receptor B (hPRB), androgen receptor
(hAR), mineralocorticoid receptor (hMR), glucocorticoid
receptor (hGR), and estrogen receptors (ER) α and β
(hERalpha and hERbeta, respectively). NOMAC and LNG
were the most potent progestogens in activating hPRB
in CHO cells. NOMAC did not display antagonistic
activity against hPRB. NOMAC, DRSP, DNG, LNG, and
progesterone were all capable of antagonizing hAR.
None of the progestogens tested (including NOMAC)
activated or antagonized hERalpha, hERbeta, or hGR or
were hMR agonists. In addition, NOMAC did not have
antimineralocorticoid activity. These experiments sup-
port the overall conclusion that NOMAC has a proges-
tational profile that is similar to progesterone.In vivo progestational activity
Progestogens antagonize estrogen action by induction
of estradiol metabolism and down-regulation of the ER
[17-20]. Progesterone down-regulation of the ER and the
agonistic versus antagonistic effect of progesterone on
uterine weight is dependent on the concentration of
plasma E2 [21]. Moreover, progesterone is far more effect-
ive in reducing ER levels in estrogen-primed tissue [22].
The effects of NOMAC treatment on the expression
of cytosolic uterine ER were studied in Sprague–Dawley
ovariectomized (OVX) rats. After recovering from ovari-
ectomy for at least 15 days, each rat received an intra-
peritoneal injection of vehicle or E2 (5 μg/rat). After 24
hours, each rat received either vehicle (n = 8), E2 only
(n = 6), E2 + progesterone (100, 250, or 950 μg/rat; n = 5
per dose), E2 +NOMAC (100, 250, or 950 μg/rat; n = 5
per dose), or E2 +medroxyprogesterone acetate (MPA;
100, 250, or 950 μg/rat; n = 5 per dose). After an add-
itional 24 hours, the rats were killed and uteri removed.
ER contained in nuclear cell fractions originating from
rat uterine cytosol were determined using a 3[H] E2
exchange assay [21,23].
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of ER in the uterus by 3-fold (Figure 2). Progesterone,
NOMAC, and MPA caused a dose-dependent inhibition
of E2-stimulated ER. When administered alone (without
E2), NOMAC, MPA, and progesterone did not influence
uterine ER. This study demonstrated that NOMAC
acted in vivo to inhibit ER expression in E2-primed rat
uterus.Antigonadotropic activity and ovulation inhibition
Paris et al. [1] and van Diepen [13] investigated the abil-
ity of NOMAC to inhibit ovulation in the rat. After 3
consecutive, regular 4-day cycles, animals in the metes-
trus phase received single subcutaneous injections of
NOMAC or progesterone at doses of 0.25, 1, or 4 mg
(n = 5-6 per dosage group) or vehicle (n = 17). In this
study, the rate of ovulation in the vehicle-treated control
animals was 76.5%. At the lowest dose (0.25 mg/rat),
NOMAC inhibited ovulation in 78.2% (5/6) of rats, indi-
cating that the 50% inhibition dose (ID50) for NOMAC
was <1.25 mg/kg. The ID50 for progesterone was
approximately 5 mg/kg. Oral NOMAC produced similar
results and suggested that oral NOMAC is at least 2
times more potent than oral LNG in inhibiting ovulation
in rats. In Cynomolgus monkeys (Macaca fascicularis),
which have a menstrual cycle very similar to the human
menstrual cycle (average Cynomolgus cycle length, 29
days; range, 26-32 days), NOMAC was also able to
inhibit ovulation. NOMAC administered for 1 cycle to 34
Cynomolgus monkeys provided effective, dose-dependent
inhibition of ovulation, which was observed in 4/11, 7/10,
and 11/11 monkeys (0.10, 0.25, and 1.00 mg/kg/day
NOMAC, respectively) [13]. The ID50 of NOMAC was
0.14 mg/kg. Treatment with NOMAC did not influence
body weight or cycle length relative to nontreatment.Figure 2 Inhibition by progestogens of estrogen-stimulated
uterine estrogen receptor content in OVX rats. ANOVA, analysis
of variance; OVX, ovariectomized; E2, 17β-estradiol; NOMAC,
nomegestrol acetate; MPA, medroxyprogesterone acetate; SD,
standard deviation. * P<0.05; ** P<0.01 compared with E2-only
treated rats (ANOVA).In vitro estrogenic and anti-estrogenic activity
Estrogens stimulate proliferation of human breast tumor
cells [24]. However, the effect of progestogens on human
breast tumor cells is more controversial. Progestogens
that interact with the ER can have a stimulatory effect
growth of T-47D and MCF-7 cells [25], whereas proges-
togens that do not interact with ER do not stimulate cell
proliferation. To determine the effect of NOMAC on
breast cancer cell growth, in the absence of E2, Cathe-
rino et al. [26] investigated the effect of NOMAC and
megestrol acetate (MAC) on growth of MCF-7 and
T-47D cells. The cells were incubated for 6 days in the
presence of NOMAC or MAC at doses up to 10–6 M
and the proliferative activity of cells grown in the pres-
ence of progestogen was determined (measured by total
DNA). As would be expected of progestogens that do
not activate ER, NOMAC and MAC at doses up to 1
μM/L did not increase proliferative activity.
Although NOMAC has no growth-stimulating activity
on breast cancer cells in the absence of E2, some evi-
dence suggests that it may also help attenuate the prolif-
erative effects of endogenous E2 by preventing E2
formation from estrone sulfate (E1S) and by enhancing
the conversion of E2 to less potent metabolites. In sup-
port of this possibility, NOMAC was able to inhibit
estrone sulfatase and 17β-hydroxysteroid dehydrogenase
activity, 2 enzymes responsible for the conversion of E1S
to E2 [27]. In T-47D cells, NOMAC (5 × 10–6 M and
5 × 10–5 M) blocked the conversion of E1S (2 × 10–6 M)
to E2 by –60% and –71%, respectively. In MCF-7 cells,
NOMAC (5 × 10–6 M and 5 × 10–5 M) blocked the con-
version of E1S (5 × 10–9 M) to E2 by –43% and –77%,
respectively.
NOMAC also had a stimulatory effect on the activity
of estrogen sulfotransferase, an enzyme that converts E1
to E1S or E2 to E2S in hormone-dependent MCF-7 and
T-47D human breast cancer cells [28]. At concentrations
of 5 × 10–8 M and 5× 10–7 M, NOMAC increased the
activity of sulfotransferase in MCF-7 cells by 60.6% and
83%, respectively. In T-47D cells, NOMAC (5 × 10–7 M)
increased estrogen sulfotransferase activity by 69.2%.
Taken together, these studies indicate that NOMAC
alone does not induce breast cancer cell growth in vitro
and may reduce the proliferative effect of E2 in these
cells by preventing conversion of E1S to more potent E2.
In vivo estrogenic and anti-estrogenic activity
Although NOMAC does not bind to or transactivate ER,
several experiments were performed to evaluate possible
estrogenic activity in vivo that could be mediated by
actions at the PR. To test this possibility, Sprague–
Dawley OVX rats (90-100 g) were treated with a single
subcutaneous injection of E2 (5 μg/rat) followed by oral
vehicle (n = 47; control; no progestogen), oral NOMAC
Table 1 Effect of progesterone, MPA, and NOMAC on the









– – – 20 21.61 ± 1.37**
0.1 – – 10 32.88 ± 2.26
0.1 Progesterone 0.3 5 32.04 ± 1.38
0.1 0.6 5 30.46 ± 1.53
0.1 0.9 5 29.78 ± 2.99
0.1 MPA 0.3 5 27.50 ± 1.08
0.1 0.6 5 24.92 ± 2.37*
0.1 0.9 5 29.34 ± 2.42
0.1 NOMAC 0.3 5 27.16 ± 3.22
0.1 0.6 5 23.72 ± 1.08**
0.1 0.9 5 23.94 ± 1.16**
Oral administrationa
– – – 40 12.31 ± 0.49
0.1 – – 31 40.99 ± 2.11
0.1 MPA 0.3 8 30.08 ± 3.92*
0.1 0.6 7 22.39 ± 3.09**
0.1 0.9 8 24.70 ± 2.27**
0.1 NOMAC 0.1 9 46.74 ± 4.48
0.1 0.3 16 29.22 ± 1.89**
0.1 0.6 28 30.97 ± 2.47**
0.1 0.9 16 25.07 ± 2.28**
0.1 1.8 9 25.09 ± 4.37**
Uterine weights (mg) are expressed as the mean ± standard deviation.
aEstradiol-benzoate was administered as a subcutaneous injection.
MPA, medroxyprogesterone acetate. * P<0.01; ** P<0.001 compared with the
estradiol-benzoate-treated control group.
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mg/rat). The percentage of rats in each group with posi-
tive vaginal smears (indicating epithelial cornification) at
56 and 72 hours after treatment with E2 was deter-
mined. Epithelial cornification occurred in 76.6% of con-
trol rats (36/47 in estrus) that received E2 only (no
progestogen). NOMAC and MPA produced dose-
dependent inhibition of epithelial cornification (Figure 3),
a strong indicator of anti-estrogenic activity. The ID50
values for NOMAC and MPA were 450 and 92 μg/rat,
respectively. A small dose of NOMAC (0.6 mg/rat) was
enough to inhibit epithelial cornification in approxi-
mately two-thirds of rats. These experiments demon-
strated that NOMAC had only anti-estrogenic activity
and prevented E2-induced vaginal cornification in OVX
rats in a dose-dependent manner.
The anti-estrogenic activity of NOMAC was further
investigated in mice using a method devised by Edgren
[29]. Three-week-old mice (8-11g) received subcutane-
ous injections of estradiol benzoate (0.1 μg/3 days) and
subcutaneous injections of progesterone, MPA, or
NOMAC (0.3, 0.6, and 0.9 mg/mouse/3 days for each
compound). In a separate study, mice received subcuta-
neous injections of estradiol benzoate (0.1 μg/3 days)
and oral doses of MPA (0.3, 0.6, or 0.9 mg/mouse/3 days)
or NOMAC for 3 consecutive days (0.1, 0.3, 0.6, 0.9, or
1.6 mg/mouse/3 days). At 24 hours after the last dose,
the uteri were removed, weighed, and dissected. In
estradiol-benzoate-treated mice, subcutaneous NOMAC
(0.6 and 0.9 mg) significantly decreased the weight of
the uterus compared with control mice that received
estradiol-benzoate but no progestogen (Table 1). High
doses of subcutaneous progesterone (0.9 mg) did not
decrease uterine weight significantly. Although a moder-
ate subcutaneous dose of MPA (0.6 mg) was able to in-
duce a statistically significant decrease in uterine weight,Figure 3 Effect of NOMAC and MPA on E2-stimulated vaginal
epithelial cornification in OVX rats. OVX, ovariectomized; E2,
17β-estradiol; NOMAC, nomegestrol acetate; MPA,
medroxyprogesterone acetate.the uteri of mice receiving the lowest and highest
dosages of MPA did not undergo statistically significant
weight reductions. Oral MPA (0.3-0.9 mg) did cause
statistically significant reductions to the weight of the
uterus (Table 1). In addition, oral NOMAC (0.3-1.8 mg)
administered over a 3-day period induced a significant
reduction in the weight of the uterus compared with con-
trol mice (subcutaneous estradiol-benzoate treatment only;
no progestogen). These experiments demonstrated that
NOMAC administration had a significant anti-estrogenic
effect in estradiol-benzoate-treated mice.
Androgenic and anti-androgenic activity
Several studies have demonstrated that NOMAC is
devoid of androgenic activity [1,13,30,31]. In some of the
initial experiments to examine androgenic activity, sexu-
ally immature, castrated male rats were treated with a
high dose of NOMAC (10 mg/rat) for 10 days; it did not
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have other androgenic or anabolic effects [1]. Although
these studies showed that NOMAC did not possess
androgenic activity in rats, it did have significant
anti-androgenic activity, which was estimated to be
between 3 to 5 times greater than that of chlormadinone
acetate (CMA) [1]. In transactivation studies, NOMAC
was also found to be an effective antagonist against hAR
[13], with much greater anti-androgenic activity than
progesterone, DNG, and DRSP, but less activity than
LNG. These results were consistent with previous find-
ings demonstrating that the binding affinity of NOMAC
for rat androgen receptor was approximately 4 times
greater than that of progesterone [30].
A previously unpublished study in mature orchidecto-
mized rats demonstrated the anti-androgenic effects of
NOMAC on male accessory organs in vivo (Figure 4). In
this study, oral NOMAC (5 or 15 mg/day) or MPA (10
or 20 mg/day) or vehicle was co-administered with tes-
tosterone propionate (100 μg/day) for 7 days. The
weights of the ventral prostate and seminal vesicles
decreased significantly in animals that received NOMAC
or MPA relative to testosterone propionate-treated con-
trols, results that were consistent with previously pub-
lished data comparing NOMAC and cyproterone acetate
[31]. In sexually mature, intact male rats that did not
receive exogenous testosterone, oral NOMAC (5 or 15
mg/rat/day), or MPA (10 or 20 mg/rat/day) for 12 days
also resulted in significant weight reductions of the ven-
tral prostate and seminal vesicles, additional evidence of
anti-androgenic activity (data not shown).
Glucocorticoid and antiglucocorticoid activity
Botella et al. [11] assessed the in vitro glucocorticoid
activity of NOMAC and other synthetic steroids relative
to a known glucocorticoid receptor (GR) agonist (dexa-
methasone) and found that NOMAC had very little
interaction with rat liver or kidney GR. NOMACFigure 4 Antiandrogenic activity of NOMAC and MPA in castrated ma
propionate (T; 100 μg/day), T +NOMAC (5 or 15 mg/day), or T +MPA (10 o
seminal vesicles determined. ANOVA, analysis of variance; NOMAC, nomege
treated controls (ANOVA).incubated with rat liver GR for 2 hours had a half max-
imal inhibitory concentration (IC50) of 167 ± 21 nmol/
L (10.3%) relative to dexamethasone (IC50, 17.2 ± 3.8
nmol/L). Although the IC50 of dexamethasone was
unchanged after 24 hours, the IC50 of NOMAC increased
to 1493 ± 807 nmol/L (1%). These results demonstrate
that NOMAC has less affinity for rat liver GR over time.
These results suggest a low association and faster dis-
sociation to rat GR of NOMAC compared with dexa-
methasone. However, this effect was not observed when
testing the glucocorticoid effect of NOMAC on hGR.
The effect of NOMAC and comparator progestogens on
the pituitary-adrenal axis was assessed in OVX rats by
measuring plasma corticosterone and the weight of the
adrenal glands. Ten days post-ovariectomy, 30-day-old
Sprague–Dawley OVX rats (n = 8-28 rats/group)
received oral vehicle (no progestogen), progesterone
(10 mg/rat/day), NOMAC (0.3-3.0 mg/rat/day), or
MPA (0.1-3.0 mg/rat/day) for 14 days. A fifth non-OVX
group received oral vehicle. On Day 15, plasma cortico-
sterone was determined in 5 rats/group and, in another
5 rats/group, adrenal glands were removed and examined
for morphological changes. The adrenal glands were
removed and weighed in the remaining rats. Comparisons
among groups were made using ANOVA methods.
Histopathology of the adrenal glands revealed that
ovariectomy (OVX controls) caused adrenal hypertrophy
(with some lipid accumulation in the adrenal cortex).
MPA and progesterone decreased the weight of adrenal
glands in OVX rats by a statistically significant margin
relative to OVX control rats (Table 2), a finding similar
to that of others [32]. In OVX rats receiving oral MPA,
a dose-dependent decrease in adrenal weight was
observed, associated with hypotrophy of the zona fasci-
culata and zona glomerulosa and moderate lipid accu-
mulation in the adrenal cortex; these are changes
consistent with inhibition of adrenocorticotropic hor-
mone secretion. In contrast to MPA, NOMAC caused ature rats. Rats were treated with vehicle (V), V + testosterone
r 20 mg/day) for 7 days and the weights of the ventral prostate and
strol acetate; MPA, medroxyprogesterone acetate. * P<0.001 vs V + T
Table 2 Effect of progesterone, NOMAC, and MPA on the







Control (No OVX) – 16 46.59 ± 1.51*
Control (OVX) – 28 53.32 ± 1.63
Progesterone
(OVX)
10 10 39.98 ± 2.15*
NOMAC (OVX) 0.3 10 58.38 ± 3.53
1 19 60.28 ± 1.89*
3 9 59.43 ± 2.03*
MPA (OVX) 0.1 8 47.28 ± 2.66*
0.3 10 37.35 ± 1.77*
1 8 27.58 ± 1.15*
3 8 20.86 ± 1.14*
Adrenal weight is shown as the mean ± the standard error of the mean.
ANOVA, analysis of variance; MPA, medroxyprogesterone acetate; NOMAC,
nomegestrol acetate; OVX, ovariectomized.
* P<0.05 vs OVX control (ANOVA).
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was associated with adrenal hypertrophy and decreased
lipid accumulation in the adrenal cortex. No statistically
significant changes in plasma corticosterone were
observed between OVX control rats and rats receiving
the test compounds. In conclusion, these data indicate
that oral NOMAC administration to OVX rats signifi-
cantly increased adrenal gland weight relative to non-
treated OVX rats that was not due to changes in plasma
corticosterone.
To directly test for anti-inflammatory activity, the
effects of NOMAC, hydrocortisone, and MPA on
cotton/wool-stimulated inflammatory responses in rats
were investigated. Sprague–Dawley male rats (weight,
80-100 g; n = 8 per group) were placed on one of the fol-
lowing once-daily oral dosing regimens for 10 days:
vehicle (negative control), NOMAC (2.5-10 mg/kg), or
MPA (2.5-10 mg/kg). On Day 7, a cotton/wool pellet
was implanted subcutaneously in all rats to induce an
inflammatory response. On Days 7-10, 2 groups of
vehicle-treated rats received twice-daily, fixed oral doses
of the glucocorticoid hydrocortisone (10 or 80 mg/kg).
On Day 10, rats in all groups were sacrificed, and the
adrenal glands and thymus were removed and weighed.
Granulomas that had formed around the cotton/wool
pellets were removed, dried for 24 hours in an oven
(80°C), and weighed. In one rat per group, implantation
zones around the pellet, thymus, and adrenals were
removed, placed in Bouin’s fixative for 48 hours, pro-
cessed, and examined with histopathological methods
for signs of vascular, cellular, and fibrous reactions (indi-
cative of inflammation).
Hydrocortisone (10 and 80 mg/kg) significantly reduced
the weight of the adrenal glands by –26% and –36%,respectively (Table 3, P<0.001). The weight of the thymus
was also decreased in rats that received hydrocortisone
(10 and 80 mg/kg) by –41% and –77%, compared with
control rats (P<0.001). Unlike hydrocortisone, NOMAC
did not cause significant weight reductions in adrenal
glands or thymus. No anti-inflammatory activity or ad-
renal cortex atrophy was observed in animals that received
the lowest dose of NOMAC (2.5 mg/kg). At all dosage
levels, MPA caused a statistically significant (P<0.01) re-
duction in adrenal gland weight. The highest dose of MPA
(10 mg/kg) decreased the weight of the thymus signifi-
cantly (P<0.05).
Granulomas indicative of inflammation formed around
the cotton/wool pellet in all groups. Hydrocortisone (10
and 80 mg/kg) inhibited the growth of granuloma tissue
around the cotton/wool implants by 18% and 27%,
respectively. In rats that received NOMAC, dose-
dependent inhibition of inflammation was not observed.
At the lowest dose (2.5 mg/kg), NOMAC inhibited the
development of granuloma tissue significantly (P<0.01),
but larger doses of NOMAC (≥5.0 mg/kg) had no sig-
nificant effect on granuloma tissue weight (P≥0.05). The
highest dose of MPA (10 mg/kg) significantly reduced
(P<0.05) granuloma tissue weight. Although a low dose
of NOMAC (2.5 mg/kg) inhibited granuloma formation,
histopathology did not reveal signs indicative of anti-
inflammatory activity or adrenal atrophy. In summary,
these data suggest that NOMAC does not inhibit the
pituitary-adrenal axis and has minimal (if any) direct
anti-inflammatory or apparent glucocorticoid activity.
Central nervous system
Ovariectomy significantly reduces circulating as well as
brain concentrations of hormonal factors known to effect
mood, such as allopregnanolone and beta-endorphin
[33,34]. In female OVX Wistar rats, oral NOMAC (0.5
and 1 mg/kg/day) significantly increased allopregnanolone
in the hippocampus, but not in other areas of the
brain [34]. NOMAC (1 mg/kg/day) also increased beta-
endorphin in the hippocampus and NOMAC (0.5 and 1
mg/kg/day) increased beta-endorphin in the hypothalamus.
In the same study, estradiol valerate (0.05 mg/kg/day)
alone increased allopregnanolone and beta-endorphin in
OVX rats. Combining 1 mg/kg/day NOMAC and estra-
diol valerate increased allopregnanolone concentrations to
values higher than with either drug alone. Coadminstra-
tion of NOMAC (1 mg/day) and estradiol valerate
increased beta-endorphin values significantly in hippo-
campus, frontal, parietal, and hypothalamic areas of the
brain, as well as plasma to values higher than with either
drug alone, and to levels similar to those observed in
unoperated controls. Coadministration of lower doses
of NOMAC (0.05, 0.1, 0.2, 0.5 mg/kg/day) and estradiol
valerate did not augment brain concentrations of beta-









Vehicle – 38.8 ± 1.4 607 ± 34 29.7 ± 1.5
Hydrocortisone 10 28.6 ± 1.1* 355 ± 42* 24.6 ± 1.4*
80 25.0 ± 0.9* 139 ± 15* 22.0 ± 1.4*
NOMAC 2.5 36.2 ± 2.1 614 ± 43 23.3 ± 1.4*
5 35.8 ± 1.7 586 ± 28 27.1 ± 2.5
10 36.7 ± 1.0 576 ± 46 26.4 ± 1.6
MPA 2.5 32.4 ± 1.0* 636 ± 25 25.4 ± 1.7
5 30.4 ± 1.5* 624 ± 42 25.8 ± 2.1
10 24.2 ± 1.4* 512 ± 20* 24.6 ± 1.9*
Sample weights (mg) are shown as the mean ± standard error of the mean. ANOVA, analysis of variance; MPA, medroxyprogesterone acetate; NOMAC,
nomegestrol acetate; * P<0.05 compared with the vehicle control group (ANOVA).
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system to influence allopregnanolone and beta-endorphin
was different from other progestogens, including proges-
terone, DRSP, MPA, and dydrogesterone [33-35].Mineralocorticoid and antimineralocorticoid activity
Mineralocorticoids (including aldosterone) deserve special
attention because they have been shown to interact with
progesterone to alter renal function in rats [36]. In the
presence of mineralocorticoid hormones, progesterone
increases the loss of sodium and chloride in urine and
inhibits aldosterone binding to mineralocorticoid recep-
tors (MRs) [36]. Progesterone [36-38] and NOMAC [39]
also inhibit [3H]-aldosterone binding to rat kidney MRs.
In contrast, derivatives of 17alpha-hydroxyprogesterone
(such as MPA and MAC) do not inhibit the binding of
[3H]-aldosterone to rat kidney MRs [11].
In 3 previously unpublished studies, the antimineralo-
corticoid activity of oral NOMAC was assessed in OVX
rats using a method similar to one described previously
[40]. In all 3 studies, Wistar rats underwent bilateral
ovariectomy to decrease the concentration of endogen-
ous progesterone (antimineralocorticoid). After a 1-week
recovery period, urine was collected overnight for base-
line assessment (sampling time: t0) of urinary sodium
[Na+] and potassium [K+]. On Day 8, rats received a pla-
cebo (oral vehicle), NOMAC, or reference compound
(spironolactone or DRSP) in the morning and urine was
collected overnight (sampling time: t1). On Days 9 and
10, rats received the same compound they received dur-
ing the morning of Day 8. Urine was also collected dur-
ing the night of Day 10 (sampling time: t3).
In the first experiment, oral NOMAC (40 and 80 mg/kg)
and oral nomegestrol (80 mg/kg) were tested alone for anti-
mineralocorticoid activity, and spironolactone (80 mg/kg)
was used as a reference antimineralocorticoid compound.Rats receiving spironolactone showed a significant
increase in the mean change (Δ)[Na+]/[K+] ratio at t1 and,
to a lesser extent, at t3, when compared with placebo
treatment, confirming that spironolactone possessed anti-
mineralocorticoid activity (Figure 5A). In contrast, the
mean Δ[Na+]/[K+] ratio remained similar to placebo at t1
and t3 after treatment with NOMAC or nomegestrol, sug-
gesting that NOMAC and nomegestrol did not have anti-
mineralocorticoid activity. In the second experiment, the
effect of E2 alone and in combination with NOMAC was
evaluated. As expected, spironolactone (80 mg/kg) again
caused a significant increase in the mean Δ[Na+]/[K+]
ratio at t1 and t3 compared with placebo (Figure 5B). In
animals receiving E2 alone, a dose-dependent decrease in
the mean Δ[Na+]/[K+] ratio was observed at t3 (statisti-
cally significant at 5 mg/kg E2). At t3, rats that received
40 mg/kg NOMAC and 0.5 or 5 mg/kg E2 also showed a
modest but significant decrease in the mean Δ[Na+]/[K+]
ratio, suggesting that NOMAC did not alter the effect of
E2. In the third experiment, the effect of the synthetic es-
trogen, EE, on mineralocorticoid activity was evaluated.
In this study, the spironolactone-derived progestogen
DRSP (40 mg/kg) and spironolactone (80 mg/kg) were
both used as reference compounds and, as expected, both
caused similar increases in the mean Δ[Na+]/[K+] ratio at
t1 and t3 compared with placebo treatment (Figure 5C).
In contrast, EE alone (0.005-0.5 mg/kg) or combined with
NOMAC (40 mg/kg) did not alter Δ[Na+]/[K+] ratio at t1
or t3. Taken together, these 3 studies indicate that
NOMAC, administered alone or co-administered with EE
or E2, does not have antimineralocorticoid activity.Effects on carbohydrate and lipid metabolism
Although progestogens chiefly interact with PR, adipose
tissue has been shown to act as an indirect metabolic
target of progesterone and E2 [41,42]. Hazard et al. [43]
BC
A
Figure 5 Mean urinary change in sodium/potassium
(Δ[Na+]/[K+]) ratio in rats after oral administration of (A)
spironolactone (SP), nomegestrol acetate (NOMAC), or
nomegestrol (NOM); (B) SP, 17β-estradiol (E2), or NOMAC/E2;
and (C) SP, drospirenone (DRSP), ethinyl estradiol (EE), or
NOMAC/EE. t1, overnight urine; t3, urine collected during last time.
Doses are in mg/kg. Results are shown as mean ± standard error of
the mean. * P<0.05; ** P<0.01 indicates the results were statistically
significant compared with placebo-treated animals (analysis of
variance).
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of progesterone, MAC, norethindrone acetate, and
NOMAC on lipid metabolism and plasma glucose in
adult female rats. MAC, a 17alpha-hydroxyprogesterone
derivative, induced significant increases in glucose, total
cholesterol, high-density lipoprotein (HDL) cholesterol,
triglycerides, and phospholipid plasma levels. After 18
days, a marked increase was observed in the weight of
parametrial adipose tissue (PAT) relative to control ani-
mals. Animals receiving norethindrone acetate also had
significant glycemia at Day 18; lipid parameters were
lowered at Day 4, and only triglycerides reverted to nor-
mal levels at Day 18. Animals receiving norethindrone
acetate had decreased body weight (–9%) relative to con-
trol animals, but PAT weight was similar to control ani-
mals. In contrast, NOMAC and progesterone did not
alter lipid or glucose metabolism or HDL cholesterol, and
plasma and tissue lipolysis remained unchanged. Animals
receiving NOMAC and progesterone both experienced a
similar increase in body weight over time as controls, but
only progesterone caused a statistically significant increase
in PAT weight (P≤0.05) relative to controls at Day 18. In
our previously unpublished studies, OVX rats receiving
vehicle or oral NOMAC (10 mg/kg/day) for 21 days had
similar levels of alkaline phosphatase, plasma glucose,
plasma insulin, triglycerides, total cholesterol, and HDL
cholesterol (Table 4).
In summary, NOMAC administration had little effect
on carbohydrate and lipid metabolism in rats. Moreover,
NOMAC and E2 administration to nonhuman primates
did not alter total cholesterol, HDL, or plasma triglycer-
ides [44,45]. These data have been confirmed in clinical
studies [46].
Effects on bone
Ovariectomy, which can induce osteopenia, can decrease
bone mineral density (BMD) in rats [47]. However, little is
known about the effect of 19-nor-progesterone (including
NOMAC) on BMD and other bone health parameters. To
determine the effect of NOMAC on BMD in the rat, sexu-
ally mature female rats (21 weeks old; n= 8 per group)
underwent OVX and received (1) once-daily subcutaneous
injections of E2 (1 μg/kg) for 90 days; (2) once-daily oral
NOMAC (1 mg/kg) for 90 days; or (3) once-daily oral
NOMAC (1 mg/kg) plus subcutaneous E2 (1 μg/kg) for 90
days. The BMD of the lumbar rachis decreased by 5% in
OVX rats, with significant changes observed as early as
the first dual-energy X-ray absorptiometry (DEXA) meas-
urement (Table 5). In the intact control group (non-OVX
rats), BMD increased over 90 days (+12%). Although E2
was able to restore BMD to a higher level than that
observed in OVX control rats, BMD was not fully restored
to levels observed in the intact, non-OVX controls. There
were no statistically significant differences between the
Table 4 Effect of 21 days treatment with 10 mg/day NOMAC on mean metabolic parameters in OVX rats compared













Intact control 124 1.06 0.61 0.48 0.58* 0.33
OVX control 150 1.04 0.71 0.49 0.70 0.38
NOMAC 156 1.03 0.72 0.54 0.72 0.40
ANOVA, analysis of variance; HDL, high-density lipoprotein; NOMAC, nomegestrol acetate; OVX, ovariectomized. N= 10 per group; * P<0.05 vs OVX control (ANOVA).
Female rats weighing 180 to 200 g were OVX or kept intact 1 week before treatment was started. Rats (n= 10) were orally treated with vehicle or 10 mg/kg/day of
NOMAC for 3 weeks. Blood samples were collected from fasting animals from the retro-orbital venous sinus under light ether anesthesia 1 hour ±30 minutes after
treatment. Plasma samples were stored at –20ºC until measuring the alkaline phosphatase, glucose, insulin, triglycerides, cholesterol, and HDL cholesterol.
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antly, NOMAC did not prevent the restorative effect of E2
on BMD in OVX rats (Table 5).
Effect on endothelial function and the cardiovascular
system
The effects of progestogens on endothelial function are
complex, partially mediated by progestogen binding to the
androgen receptor (AR), ER, GR, or MR [48]. However,
the effect of E2 on endothelial function is unequivocal:
E2 can enhance the production of endothelial nitric oxide
synthase (eNOS), increasing the release of nitric oxide,
which can relax vascular smooth muscle, inhibit
platelet aggregation, and inhibit the progression of
atherosclerosis [49]. In contrast to the effects of E2,
the effect of progestogens on endothelium-dependent
vasodilation and antiplatelet activity are less well
understood. It has been proposed that progestogens
with non-androgenic activity and antimineralocorti-
coid properties are not deleterious to cardiovascular
health, especially when used in combination with E2 [48].
NOMAC, which displays moderate anti-androgenicTable 5 Effect of NOMAC on osteodensitometry (DEXA) meas
Treatment
Day 20
Intact control† 104.8 ± 1.4
% treatment of intact control 100
OVX control† 94.4 ± 2.3
% treatment of intact control −9.9
E2 (1 μg/kg/day)† 98.2 ± 0.7
% treatment of OVX control +4.0
NOMAC (1 mg/kg/day)† 92.7 ± 0.8
% treatment of OVX control −1.8
E2 (1 μg/kg/day) +NOMAC (1 mg/kg/day)† 98.7 ± 1.1
% treatment of OVX control +4.6*
ANOVA, analysis of variance; DEXA, dual-energy X-ray absorptiometry; E2, 17β-estrad
of DEXA values and are expressed as the mean ± standard error of the mean. * P<0
At 3-week intervals, osteodensitometry measurements of the lumbar vertebrae (L1
femur and L5 vertebra removed, and dynamic osteodensitometric measurements wactivity, can stimulate nitric oxide synthesis, eNOS ac-
tivity, and eNOS expression in human endothelial cells
derived from human umbilical veins [50] and does not
impair estrogen-dependent induction of eNOS [50]. In
a comparative study, MPA and progesterone markedly
decreased eNOS mRNA and protein in endothelial
cells, whereas LNG and NOMAC had minimal effects
on eNOS [51].
NOMAC appears to have a neutral effect on cardiovas-
cular function. Intramuscular administration of NOMAC
(0.5 or 2.5 mg/kg) over 4 hours in halothane anesthetized
male beagle dogs (n= 5 per group) did not produce statis-
tically significant differences in blood pressure, heart rate,
femoral blood flow and resistance, carotid flow and
resistance, cardiac flow, total peripheral resistance, or
maximal ventricular performance when compared with
a vehicle-treated control group (data on file with MSD).
In female Cynomolgus monkeys, supramaximal single
oral doses of NOMAC (5, 20, and 80 mg/kg) did not
alter hemodynamics (heart rate and arterial blood pres-
sure) or cardiac electrophysiologic parameters (PQ,
QRS, QT, and heart rate-corrected QT intervals) over aurements of L1 to L5 of the lumbar rachis
DEXA measurements (%)
Day 41 Day 62 Day 90
105.5 ± 2.5 105.9 ± 1.5 108.0 ± 1.4
100 100 100
95.5 ± 1.7 97.0 ± 2.8 95.1 ± 2.7
−9.4 −8.4 −12
100.8 ± 1.4 103.6 ± 1.7 102.8 ± 1.8
+5.5 +6.8* +8.1**
93.4 ± 0.5 92.2 ± 1.1 93.2 ± 2.3
−2.3 −4.9 −2.0
97.5 ± 1.9 102.0 ± 1.0 101.5 ± 1.1
+2.1 +5.2* +6.7*
iol; NOMAC, nomegestrol acetate; OVX, ovariectomized. † Data are percentages
.05; ** P<0.01 compared with OVX control animals (ANOVA).
to L6) were made using DEXA. After 90 days, the animals were sacrificed, the
ere made.
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were much higher than the ID50 reported for ovulation
inhibition (0.14 mg/kg) in the same species [13]. Taken
together, these studies suggested that NOMAC did not
affect parameters of cardiovascular function in dogs and
nonhuman primates. NOMAC may have an inhibitory
effect on prostaglandin-induced contractions of uterine
smooth muscle [52], but any effect on prostanoid-mediated
effects in the vasculature is not known.Pharmacokinetics and metabolism
NOMAC pharmacokinetics have been investigated most
extensively in humans [53,54]. In women, oral administra-
tion of 2.5 mg NOMAC per day results in rapid absorption
with a time to maximal concentration of approximately 1.5
hours. Elimination half-life is approximately 46 hours and
steady state is reached after 5 days of dosing.
Nomegestrol acetate is metabolized by hepatic cyto-
chrome P450 (CYP) system enzymes, including CYP3A3,
CYP3A4, and CYP2A6 into metabolites with little or no
effect on progesterone receptor activity [55]. As such,
there is a possibility for drug interactions when com-
bined with inducers or inhibitors of the CYP system,
such as rifampicin or ketoconazole. Excretion is via the
urine and feces [55].Conclusions
NOMAC, a highly selective contraceptive progestogen
derived from 19-nor-progesterone, is a full PR agonist
without significant agonistic or antagonistic ER activity.
NOMAC binds with strong affinity to PR in hormone-
sensitive cells derived from rat, rabbit, or human. It pos-
sesses strong antigonadotropic activity (dose-dependent
inhibition of ovulation in rats and nonhuman primates)
and has indirect, PR-mediated anti-estrogenic effects. In
addition, NOMAC does not exhibit androgenic activity
and has moderate anti-androgenic activity in rats. It is
also devoid of glucocorticoid and antimineralocorticoid
activity and does not appear to adversely affect lipid or
carbohydrate metabolism, BMD, endothelial function, or
hemodynamic parameters in selected animal models.
NOMAC combined with E2 has been developed as a
new monophasic oral contraceptive [5-10].Abbreviations
Bmax: Maximum concentration of binding sites; BMD: Bone mineral density;
CHO: Chinese hamster ovary; CMA: Chlormadinone acetate; COC: Combined
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DNG: Dienogest; DRSP: Drospirenone; E1S: Estrone sulfate; E2: 17β-estradiol;
EE: Ethinylestradiol; eNOS: Endothelial nitric oxide synthase; hAR: Human
androgen receptor; HDL: High-density lipoprotein cholesterol;
hERalpha: Human estrogen receptor α; hERbeta: Human estrogen receptor β;
hGR: Human glucocorticoid receptor; hMR: Human mineralocorticoidreceptor; hPRB: Human progesterone receptor B; IC50: Half maximal
inhibitory concentration; ID50: 50% inhibition dose; kd: Equilibrium;
k−1: Dissociation rate constant; LNG: Levonorgestrel; MAC: Megestrol acetate;
MPA: Medroxyprogesterone acetate; MR: Mineralocorticoid receptor;
[Na+]/[K+]: Sodium/potassium ratio; NETAC: Norethisterone acetate;
NOMAC: Nomegestrol acetate; OVX: Ovariectomized; PAT: Parametrial
adipose tissue; PR: Progesterone receptor; RBA: Relative binding affinity;
SD: Standard deviation.
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